Progression‐free survival · adults with cancer receiving anthracyclines
Dexrazoxane may leads to lower progression‐free survival Defined as time from first date of… compared with no cardioprotective intervention or placebo (low certainty).
3 findings from 1 review
Partial response (partial or complete response) · adults with cancer receiving anthracyclines
Dexrazoxane showed no clear difference in tumour response rate Defined as number of complete or partial… compared with no cardioprotective intervention or placebo (moderate certainty).
1 finding from 1 review
Quality of life · adults with cancer receiving anthracyclines
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival: Median length of · women with advanced EOC after PDS
Small‐volume residual disease (SVRD) < 1 cm probably leads to higher overall survival: Median length of compared with NMRD (moderate certainty).
1 finding from 1 review
Progression‐free survival · women with advanced EOC after primary IDS
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival: Median length of · women with advanced EOC after primary IDS
It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes overall survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (very low certainty).
1 finding from 1 review
Progression‐free survival · women with advanced EOC after primary IDS
It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes progression‐free survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (very low certainty).
1 finding from 1 review
Overall survival: Median length of · women with advanced EOC after primary IDS
It is very uncertain whether residual disease (RD) > 0 cm changes overall survival: Median length of compared with NMRD (very low certainty).
1 finding from 1 review
Progression‐free survival · women with advanced EOC after primary IDS
It is very uncertain whether residual disease (RD) > 0 cm changes progression‐free survival: Median length of compared with NMRD (very low certainty).
1 finding from 1 review
Progression‐free survival · women with advanced EOC after PDS
Small‐volume residual disease (SVRD) < 1 cm probably leads to higher progression‐free survival: Median length of compared with NMRD (moderate certainty).
1 finding from 1 review
Overall survival: Median length of · women with advanced ovarian cancer after PDS
Large‐volume residual disease (LVRD) > 1 cm probably leads to higher overall survival: Median length of compared with no macroscopic residual disease (NMRD) (moderate certainty).
1 finding from 1 review
Progression‐free survival · women with advanced ovarian cancer after PDS
Large‐volume residual disease (LVRD) > 1 cm probably leads to higher progression‐free survival: Median length of compared with no macroscopic residual disease (NMRD) (moderate certainty).
1 finding from 1 review
Overall survival: Median length of · women with advanced EOC after PDS
Large‐volume residual disease (LVRD) > 1 cm probably leads to higher overall survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (moderate certainty).
1 finding from 1 review
Progression‐free survival · women with advanced EOC after PDS
Large‐volume residual disease (LVRD) > 1 cm probably leads to higher progression‐free survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (moderate certainty).
1 finding from 1 review
Overall survival: Median length of · women with advanced EOC after primary IDS
It is very uncertain whether small‐volume residual disease (SVRD) (< 1 cm) changes overall survival: Median length of compared with NMRD (very low certainty).
1 finding from 1 review
Progression‐free survival · women with advanced EOC after primary IDS
1 finding from 1 review
Overall survival: Median length of · women with advanced EOC after primary IDS
It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes overall survival: Median length of compared with no macroscopic residual disease (NMRD) (very low certainty).
1 finding from 1 review
Intervention not reported
Invitation versus control: uptake of screening · women for cervical screening
The intervention probably leads to higher invitation versus control: uptake of screening (moderate certainty).
1 finding from 1 review
Intervention not reported
GP invitation letter versus invitation letter from other authority sources: uptake of screening · women for cervical screening
It is very uncertain whether the intervention changes GP invitation letter versus invitation letter from other authority… (very low certainty).
1 finding from 1 review
Intervention not reported
Personal invitation versus invitation letter: uptake of screening · women for cervical screening
The intervention may leads to higher personal invitation versus invitation letter: uptake of screening (low certainty).
1 finding from 1 review